What is Regeneron Pharmaceuticals's intangibles (net)?

Regeneron Pharmaceuticals (REGN) reported intangibles (net) of $1.31B in Q2 2026.

What does intangibles (net) mean?

Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.

Regeneron Pharmaceuticals REGN Intangibles (Net)

Intangibles (Net) at other companies

AmgenAMGN

$20.67B-16.2%

GlaukosGKOS

$127.15M-53.0%

PrecigenPGEN

$2.86M-30.8%

Other financials

Income statement

See full

Revenue$4.3B+16.7%

Operating income$1.3B+19.8%

Net income$1.3B-6.8%

EPS (diluted)$12.23-4.5%

Balance sheet

See full

Cash & equivalents$2.5B+22.3%

Total debt$2.7B+0.1%

Total equity$31.7B+5.9%

Total assets$41.7B+9.2%

Cash flow

See full

Operating cash flow$813.0M-29.0%

CapEx$240.2M+9.7%

Free cash flow$572.8M-38.1%

Valuation

See full

Market cap$72.91B+21.8%

Enterprise value$73.15B+20.8%

P/E16.8×+3.4×

P/S4.7×+0.5×

Profitability

See full

Gross margin94.9%—

Operating margin24.7%-2.3pp

Net margin27.9%-3.5pp

FCF margin24.2%-2.9pp

Returns & leverage

See full

Return on equity14%-1.3pp

Debt / equity0.1×0.0×

Current ratio3.3×-1.3×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's intangibles (net)?: Regeneron Pharmaceuticals (REGN) reported intangibles (net) of $1.31B in Q2 2026.
What does intangibles (net) mean?: Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.